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Abstract
The Fungitell assay (FA) and the Wako β-glucan test (GT) are employed to measure the
serum/plasma 1,3-β-D-glucan (BDG), a well-known invasive fungal disease biomarker.
Data to convincingly and/or sufficiently support the GT as a valuable alternative to the FA
are yet limited. In this study, we evaluated the FA and the GT to diagnose invasive aspergil-
losis (IA), invasive candidiasis (IC), and Pneumocystis jirovecii pneumonia (PJP). The FA
and GT performances were compared in sera of patients with IA (n = 40), IC (n = 78), and
PJP (n = 17) with respect to sera of control patients (n = 187). Using the manufacturer’s cut-
off values of 80 pg/mL and 11 pg/mL, the sensitivity and specificity for IA diagnosis were
92.5% and 99.5% for the FA and 60.0% and 99.5% for the GT, respectively; for IC diagnosis
were 100.0% and 97.3% for the FA and 91.0% and 99.5% for the GT, respectively; for PJP
diagnosis were 100.0% and 97.3% for the FA and 88.2% and 99.5% for the GT, respec-
tively. When an optimized cutoff value of 7.0 pg/mL for the GT was used, the sensitivity and
specificity were 80.0% and 97.3% for IA diagnosis, 98.7% and 97.3% for IC diagnosis, and
94.1% and 97.3% for PJP diagnosis, respectively. At the 7.0-pg/mL GT cutoff, the agree-
ment between the assays remained and/or became excellent for IA (95.1%), IC (97.3%),
and PJP (96.5%), respectively. In conclusion, we show that the GT performed as well as the
FA only with a lowered cutoff value for positivity. Further studies are expected to establish
the equivalence of the two BDG assays.
Introduction
Invasive aspergillosis (IA), invasive candidiasis (IC), and Pneumocystis pneumonia (PJP, previ-
ously known as PCP) represent the most prevalent invasive fungal diseases (IFDs) worldwide
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[1]. These diseases mainly affect immunocompromised (or immunosuppressed) hosts, causing
estimated over 1.6 million deaths annually [2]. Causative agents of IC include different Can-
dida species [3], whereas the main cause of IA remains Aspergillus fumigatus [4] and PJP is
uniquely caused by Pneumocystis jirovecii, formerly Pneumocystis carinii [5]. As IFD symp-
toms can be subtle and/or nonspecific, it is difficult to identify and treat the cause of disease,
especially in patients with hematological malignancies [6]. Furthermore, microbiological con-
firmation of IFD with conventional, culture-dependent methods may yield false-negative
results [7], hence, molecular, culture-independent methods to enhance the diagnostic sensitiv-
ity need to be developed [8]. Thus, pending the microbiological diagnosis, an empirical treat-
ment targeting infectious and non-infectious causes may be necessary [6].
As broad fungal biomarker for IFD (the only notable exception are mucormycosis, crypto-
coccosis, and blastomycosis) [9–12], serum 1,3-β-D-glucan (BDG) has shown wide utility in
specific clinical settings [13], including IA, IC, and PJP [14]. In a meta-analysis, He et al.
focused on the accuracy of cutoff values to diagnose IFD obtained with BDG detection assays
[15]. One was the Fungitell assay (FA; Associates of Cape Cod, East Falmouth, MA), FDA
cleared and Conformité Européenne (CE) marked, which has been most used in the Western
Hemisphere (Europe and United States), and another was the Wako β-glucan test (GT; FUJI-
FILM Wako Pure Chemical Corporation, Osaka, Japan), CE marked, which has recently been
introduced in Europe.
Both assays rely on the BDG ability to activate factor G, a serine protease zymogen, in the
Limulus (horseshoe crab) coagulation cascade. Activated factor G converts the inactive pro-
clotting enzyme to the active form, which in turn cleaves an artificial substrate used for colori-
metric (FA) or turbidimetric (GT) detection. Although BDG concentrations are measured
through spectrophotometric readings, dissimilarity of cutoff values between the assays may be
related to differences in the standards and/or affinity/reactivity of reagents in each assay [16].
Using the proposed 80 pg/mL (FA) and 11 pg/mL (GT) cutoff values [15], a recent comparison
of the two assays for PJP diagnosis showed GT to be more specific and FA to be more sensitive,
at a statistically significant level [17]. Interestingly, the sensitivity of GT equaled that of FA (at
a cutoff of�60 pg/mL) and the specificity was significantly better than that of the FA, when
the GT cutoff value lowered from 11 pg/mL to 3.616 pg/mL [17]. Consistently, previous work
showed sensitivities of the FA for both IC (i.e., candidemia) and PJP diagnoses to be superior
to those of the GT [18]. Again, lowering the GT cutoff value to�3.8 pg/mL resulted in sensi-
tivities of the GT that became acceptable for candidemia (with a decreasing specificity from
98.0% to 91.0%) and excellent for PJP, respectively [18]. However, while more data are
required to support the GT as a valuable alternative to the FA (especially for patients with can-
didemia), not enough data exist about the GT to diagnose IA.
Therefore, we compared the performance of the GT with that of the FA in well-character-
ized groups of patients with IA, IC, and PJP, with reference to appropriate control patients.
Similar to previous studies [17, 18], we also tried to define the optimal GT cutoff values which
could allow to reliably exclude IFD (mainly due to Aspergillus, Candida, or P. jirovecii).
Materials & methods
Ethics statement
This study was conducted at the Fondazione Policlinico Universitario A. Gemelli (FPG)
IRCCS of Rome, Italy, and was approved by the Ethics Committee of the FPG (application
number 38367/19) and a waiver of informed consent was granted. Sample processing and data
analysis were performed anonymously.
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Study design
We conducted a retrospective performance assessment study on archived patients’ serum sam-
ples, which had been collected as part of routine clinical care at the FPG IRCCS, a large tertiary
care hospital in Rome, Italy. We used serum instead of plasma samples because of our previous
findings showing that the two sample types may be considered equivalent [19]. Samples were
from adult patients (mainly oncology/hematology patients) who were classified as having
proven or probable IFD according to the 2008 European Organization for the Research and
Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria [20]. Samples were also
from patients who were classified as having PJP if they had clinical signs and symptoms of
respiratory infection (i.e., dyspnea, cough, or hypoxemia) supported with radiological findings
(e.g., diffuse ground glass opacities on chest radiograph) and with positive Pneumocystis-spe-
cific PCR and/or immunofluorescence staining results of respiratory samples [21]. To enhance
the robustness of the analysis, only patients with proven or probable IFDs were evaluated as
IFD cases. Serum samples from patients who had major risk factors for IFD but who did not
meet the criteria for proven or probable disease (i.e., who had no evidence of IFD) were
included as controls. Furthermore, no diagnoses were based on detection of BDG (see below),
which is part of the mycological criteria for the 2008 EORTC/MSG classification of patients
with proven/probable/possible or no IFD [20]. At the time of writing this article—and shortly
after completion the study, the EORTC/MSG education and research consortium updated def-
initions of IFDs [22]. However, according to the 2019 EORTC/MSG criteria, no reclassifica-
tion was required for either IA or IC, while PJP cases were all classifiable as proven IFD, in our
study [22].
We initially considered all the patients with a first serum BDG sample collected for routine
mycological testing eligible. Then, we included only the patients for whom a classification as
proven or probable IA (or IC) according to the 2008 EORTC/MSG definitions was available.
All patients’ samples were from the closest time (± 2 days) when evidence or no evidence of
IFD was obtained for cases and controls, respectively, and were stored at –80˚C until the study
time.
Serum BDG measurement
Before BDG testing, frozen serum samples were thawed at room temperature and briefly vor-
texed. The same investigator tested each sample’s aliquots with the FA and the GT in parallel
and in a blinded manner for each patient’s disease classification at the time of testing. The two
assays were performed in accordance with the manufacturer’s instructions. In both assays, the
BDG measurement relies on a modification of the Limulus amebocyte lysate (LAL), which
results in colorimetric (FA) or turbidimetric (GT) reaction changes. Briefly, for the FA 5 μL of
serum (in duplicate) was used and the LAL reaction was monitored at 37˚C for 40 min in an
ELx808 microplate reader (BioTek Instruments, Winooski, VT). By comparing with a stan-
dard curve, the mean optical density change over time was calculated to determine the sam-
ple’s BDG concentration. A positivity threshold of 80 pg/mL was used throughout the study.
For the GT, 100 μL of serum was used and the LAL reaction (i.e., gelation) was monitored at
37˚C for a maximum of 90 min in a MT-6500 toxinometer (FUJIFILM Wako Pure Chemical
Corporation). By comparing with a calibration curve (supplied with each lot by the manufac-
turer), the gelation time was calculated to determine the sample’s BDG concentration. A posi-
tivity threshold of 11 pg/mL was initially used in the study (see below for positivity threshold
optimization). Samples with positive results of> 500 pg/mL (FA) or > 600 pg/mL (GT) were
diluted and retested.
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Data collection and statistical analysis
Statistical analysis was performed using GraphPad Prism version 8.2 (GraphPad Software, La
Jolla, CA) and MedCalc Statistical Software version 19.0.7 (MedCalc Software bvba, Belgium).
Patients’ demographics and BDG data were expressed as percentages or medians with inter-
quartile ranges (IQR), respectively. To determine sensitivity and specificity of BDG assays,
together with their respective 95% confidence intervals (CIs), we constructed 2 × 2 tables using
IFD (IA, IC, or PJP) patients as true cases and non-IFD patients as controls. For both assays,
receiver operating characteristic (ROC) curves were generated and cutoff values were derived
to assess the diagnostic accuracy of serum BDG for case (IFD) versus control (non-IFD)
patients. The highest Youden index indicated the optimal BDG cutoff. Variables were com-
pared using chi-square test and Mann-Whitney U test, as appropriate, whereas differences in
performance parameters between BDG assays were assessed using McNemar’s test. Agreement
between BDG assays was determined by Spearman’s correlation, whereas the strength of agree-
ment was determined by Cohen’s kappa statistic. Thus, values higher than 0.80 represented
excellent agreement, values between 0.80 and 0.4 represented substantial to moderate agree-
ment, and values lesser than 0.4 represented fair to slight agreement. Statistical significance
was set at a < .05 P-value.
Results
Study samples
Table 1 shows demographics for the 322 patients from whom 322 serum samples were tested
with two BDG assays (FA and GT), of which 78 samples were from proven IC (75 candidemia
and 3 intraabdominal candidiasis) cases, 40 samples from probable IA (38 pulmonary and 2
disseminated aspergillosis) cases, and 17 samples from PJP cases. For all 135 cases, fungal dis-
ease classification (proven or probable) was obtained as previously described [20, 21]. We also
included 187 samples from 187 patients, for whom clinical, radiographic, and microbiological
findings indicated no evidence of IFD (controls). Table 2 shows details about the mycological
evidence used to classify the 135 cases as IFD.
Performances of the FA and the GT
The FA (cutoff for positivity,�80 pg/mL) and the GT (cutoff for positivity,�11 pg/mL) gave
positive results in 132 (97.8%) and 110 (81.5%) of 135 IFD samples, respectively. Of 187
Table 1. Characteristics of 322 patients from whom serum samples were tested for BDG measurementa.
Value for patients with:
IA (n = 40) IC (n = 78) PJP (n = 17) No IFD (n = 187)
Median (interquartile range) age, years 53.0 (38.7–60.2) 52.5 (40.2–60.0) 52.0 (33.0–64.0) 54.0 (42.0–68.0)
Sex, male/female 18/22 34/44 7/10 90/97
Underlying condition, no. of patients (%)
Abdominal surgery 0 (0.0) 6 (7.7) 0 (0.0) 15 (8.0)
Solid tumor 9 (22.5) 22 (28.2) 2 (11.8) 23 (12.3)
Haematologic malignancy/HSCT 23 (57.5) 2 (2.6) 7 (41.2) 92 (49.2)
Otherb 8 (20.0) 48 (61.5) 8 (47.0) 57 (30.5)
BDG, 1,3-β-D-glucan; IA, invasive aspergillosis; IC, invasive candidiasis; PJP, Pneumocystis jirovecii pneumonia; IFD, invasive fungal disease; HSCT, hematopoietic
stem cell transplantation.
a BDG testing was performed in parallel with the Fungitell assay (FA) and the Wako β-glucan test (GT).
b Includes patients in intensive care and infectious disease units.
https://doi.org/10.1371/journal.pone.0236095.t001
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control samples, 182 (97.3%) and 186 (99.5%) had negative results with the FA and the GT,
respectively. The one patient with a false-positive result by the GT was highly positive by the
FA. Overall, the median BDG concentration was 398 pg/mL with the FA and 31.63 pg/mL
with the GT. In IA cases, the median (IQR) BDG concentrations were 201 (119–377) pg/mL
and 14.07 (7.45–41.46) pg/mL for the FA and the GT, respectively. These levels were signifi-
cantly higher than the levels in controls (0 (0–11) and 0 (0–0), respectively; P< .0001). Using
the aforementioned cutoff values, the percentages of sensitivity and specificity were 92.5 and
99.5 for the FA, and 60.0 and 99.5 for the GT, respectively (Table 3). The sensitivity of FA was
significantly greater than the sensitivity of GT (92.5% versus 60.0%, P< .001).
In IC cases, the median (IQR) BDG concentrations were 516 (250–837) pg/mL and 45.57
(16.10–109.9) pg/mL for the FA and the GT, respectively. These levels were significantly higher
than the levels in controls (P< .0001). Using the aforementioned cutoff values, the percentages
of sensitivity and specificity were 100.0 and 97.3 for the FA, and 91.0 and 99.5 for the GT,
respectively (Table 3). The sensitivity of FA was significantly greater than the sensitivity of GT
(100.0% versus 91.0%, P< .001).
In PJP cases, the median (IQR) BDG concentrations were 512 (404–639) pg/mL and 46.88
(26.43–166.3) pg/mL for the FA and the GT, respectively. These levels were significantly higher
than the levels in controls (P< .0001). Using the aforementioned cutoff values, the percentages
of sensitivity and specificity were 100.0 and 97.3 for the FA, and 88.2 and 99.5 for the GT,
respectively (Table 3). The sensitivity of FA was significantly greater than the sensitivity of GT
(100.0% versus 88.2%, P = .01).
To improve the GT diagnostic performance, we determined the optimal positivity threshold
for the GT (7.0 pg/mL) with the highest Youden index, which corresponds to the maximal sen-
sitivity and specificity combination. As depicted in Fig 1, ROC analysis for proven/probable
IFD versus no IFD at the optimized cutoff value generated an area under the curve (AUC) of
0.992 (95% CI, 0.975–0.999). Using the 7.0-pg/mL cutoff, the percentages of sensitivity and
Table 2. Mycological characteristics of IFD casesa.
Characteristic IA cases (N = 40) IC cases (N = 78) PJP cases (N = 17)
n % n % n %
Proven IFD
By culture – – 75 96.1 NA –
By histology – – 3 3.8 NA –
By immunofluorescence NA – NA – 17b 100
Probable IFD
By galactomannan antigen tested in:
Serum 37c 92.5 NA – NA –
BALF 5d 12.5 NA – NA –
CSF 2e 5.0 NA – NA –
NA, Not applicable; BALF, bronchoalveolar lavage fluid; CSF, cerebrospinal fluid.
a All IFD cases were classified as described in the text.
b 15 cases were also PJP-specific PCR positive.
c The median (interquartile range) value of galactomannan index (optical density [OD] of sample/OD of cutoff control) was 1.6 (1.3–2.1). Indices of �0.5 were
considered positive.
d Two cases had positive galactomannan detection results also in serum samples. Indices were 0.8 (serum) and 1.5 (BALF) in one case and 0.9 (serum) and 2.2 (BALF) in
the other case.
e Two cases had positive galactomannan detection results also in CSF samples.
https://doi.org/10.1371/journal.pone.0236095.t002
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specificity for the diagnosis of proven/probable IFD were 80.0 and 97.3 for IA, 98.7 and 97.3
for IC, and 94.1 and 97.3 for PJP, respectively (Table 3). Only for IA, the sensitivity of FA
remained significantly greater than the sensitivity of GT (92.5% versus 80.0%, P< .03). Simi-
larly, we performed a ROC analysis for the FA using an optimized cutoff of 79.0 pg/mL, and
this resulted in an AUC of 0.990 (95% CI, 0.972–0.998). Additionally, we tried to define
whether a different cutoff value would be required for IA compared to IC or PJP. The values
for GT determined with the highest Youden index were 2.6 pg/mL for IA and 7.0 pg/mL for
both IC and PJP, whereas those for FA were 79 pg/mL for IA, 105 pg/mL for IC, and 88 pg/mL
for PJP.
Comparability of the FA and GT results
Assessing the quantitative agreement between the assays showed that a significant correlation
between the BDG levels measured by the FA and the GT for IFD and non-IFD patient samples
(Fig 2). In particular, these levels correlated significantly—although differently—for the IA
(r = 0.670 and P< .0001; n = 40), IC (r = 0.703 and P< .0001; n = 78), and PJP (r = 0.667 and
Table 3. Performance of the Fungitell assay and the Wako β-glucan test using indicated cutoffs to distinguish
between IFD and non-IFD patientsa.
Parameter Fungitell assay result
(cutoff of�80 pg/mL)
Wako β-glucan test result
(cutoff of�11 pg/mL)




True positives 78 71 77
False negatives 0 7 1
True negatives 182 186 182
False positives 5 1 5
Sensitivity, % (95% CIb) 100.0 (95.3–100.0) 91.0 (82.6–95.5) 98.7 (93.0–99.9)
Specificity, % (95% CI) 97.3 (93.8–98.8) 99.5 (97.0–99.9) 97.3 (93.8–98.8)
Invasive aspergillosis,
n = 40
True positives 37 24 32
False negatives 3 16 8
True negatives 182 186 182
False positives 5 1 5
Sensitivity, % (95% CI) 92.5 (80.1–97.4) 60.0 (44.6–73.6) 80.0 (65.2–89.5)
Specificity, % (95% CI) 97.3 (93.8–98.8) 99.5 (97.0–99.9) 97.3 (93.8–98.8)
Pneumocystis jirovecii
pneumonia, n = 17
True positives 17 15 16
False negatives 0 2 1
True negatives 182 186 182
False positives 5 1 5
Sensitivity, % (95% CI) 100.0 (81.5–100) 88.2 (65.6–97.9) 94.1 (73.0–99.7)
Specificity, % (95% CI) 97.3 (93.8–98.8) 99.5 (97.0–99.9) 97.3 (93.8–98.8)
a Serum samples from 135 patients with invasive fungal disease (IFD) and from 187 patients without evidence of IFD
(non-IFD controls) were tested with the Fungitell assay (FA) and the Wako β-glucan test (GT). The manufacturers’
cutoff values (FA,�80 pg/mL, and GT, �11 pg/mL) and, only for the GT, the optimized cutoff value (�7 pg/mL)
were used as sample’s positivity thresholds.
b CI, confidence interval.
https://doi.org/10.1371/journal.pone.0236095.t003
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P = .004; n = 17) patient samples. Assessing the qualitative agreement between the assays
showed that an excellent (or substantial) concordance regarding the results (positive/negative)
obtained with the FA (cutoff for positivity,�80 pg/mL) and GT (cutoff for positivity,�11 pg/
mL). This occurred with the samples from patients with IFD (91.8% agreement; Cohen’s
kappa statistic, 0.82), IA (91.6% agreement; Cohen’s kappa statistic, 0.67), IC (95.0% agree-
ment; Cohen’s kappa statistic, 0.88), and PJP (96.0% agreement; Cohen’s kappa statistic, 0.76),
respectively. Using the optimized GT cutoff value (�7.0 pg/mL), the concordance between the
assays remained and/or became perfect for the samples from patients with IFD (95.6% agree-
ment; Cohen’s kappa statistic, 0.91), IA (95.1% agreement; Cohen’s kappa statistic, 0.83), IC
(97.3% agreement; Cohen’s kappa statistic, 0.93), and PJP (96.5% agreement; Cohen’s kappa
statistic, 0.81), respectively.
Discussion
To the best of our knowledge, two retrospective case-control studies have carefully evaluated
the GT—the last approved BDG assay on the European market of s—in comparison with the
FA in serum samples [17, 18]. Using a similar study design, we compared the GT with the FA
to diagnose IFD in 322 patients categorized into IC (n = 78), IA (n = 40), PJP (n = 17), and
non-IFD (n = 187) groups. Indeed, we established the overall GT and FA performances in two
patient groups (135 with IFD and 187 without IFD), as well as the specific GT and FA perfor-
mances in the IA, IC, and PJP groups with respect to the non-IFD group. Importantly, to com-
pare the GT with the FA results, we followed the strategy of testing all archived patient samples
in parallel, which reduces the bias due to probability of BDG degradation during sample stor-
age, as successfully shown [17]. In contrast, Friedrich et al. performed FA measurement at the
time of sampling and GT measurement on long-term stored samples [18].
Fig 1. Receiver operating characteristic (ROC) curves of the GT (A) and the FA (B). The optimized thresholds for positivity in both
assays (7.0 pg/mL and 79 pg/mL, respectively) are marked with a dot.
https://doi.org/10.1371/journal.pone.0236095.g001
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By applying the manufacturer’s recommended cutoffs for positivity, we showed that the
sensitivity of the FA was higher than the sensitivity of the GT in IFD patients overall (97.8%
versus 81.5%, respectively) and, in particular, IA (92.5% versus 60.0%, respectively), IC (100%
versus 91.0%, respectively), or PJP (100% versus 88.2%, respectively) patients. While the PJP
values in our study are very similar to those reported by Friedrich et al. in PJP patients (sensi-
tivity of FA and GT were 100% and 88.9%, respectively) [18], our IC values differ substantially
from those reported by Friedrich et al. in candidemia patients (sensitivity of FA and GT were
86.7% and 42.5%, respectively) [18]. However, our findings are surprising, particularly if com-
pared to the results of several meta-analyses published over recent years [9–11]. The pooled
sensitivity and specificity of BDG for invasive fungal infections (excluding P. jirovecii infec-
tions) varied from 76.0% and 85.0% [10], 76.8% and 85.3% [9] to 80.0% and 82.0% [11],
respectively. Conversely, in one meta-analysis [11], the pooled sensitivity and specificity for
PJP were 96.0% and 84.0%, respectively.
Fig 2. Correlation between the BDG concentrations (pg/mL) determined by the FA and GT assays.
https://doi.org/10.1371/journal.pone.0236095.g002
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In agreement with the results by meta-analyses [9–11] but in marked contrast with those by
Friedrich et al. [18], one study [23] showed a sensitivity of 67.0%—neighbor, albeit still distant,
to ours—and a specificity of 93.0% for the GT in a similar-sized cohort of patients with candi-
demia. Like in the Friedrich et al.’s study [18], applying a decreased cutoff of 7 pg/mL allowed
Dichtl et al. to obtain a sensitivity of 73.0%, while specificities in both the studies remained as
high as 91.0% [18] and 93.0% [23]. Another study by Dichtl et al. [24] conducted in the setting
of PJP, showed that the specificity of GT—using an 11-pg/mL cutoff—was 100% in 25 control
individuals who tested negative for P. jirovecii DNA by quantitative real-time PCR from respi-
ratory samples. In the same study [24], the GT sensitivity increased from 86.0% to 91.0% after
exclusion of the cases with slightly positive PCR results—that are usually negative in micros-
copy. Thus, our data unravel unexpected features of both GT and FA, which seem to subvert
the paradigms of specificity as a “FA weakness” and of sensitivity as a “GA weakness” [25].
The reasons for conflicting results among studies are unknown, but we cannot exclude the
influence of factors as a possible explanation for the observed differences in BDG assays’ sensi-
tivity and specificity. For example, findings from stratified (subgroup) analyses in two inde-
pendent meta-analysis studies led to observe a lower EORTC/MSG diagnostic accuracy
attributable to lower sensitivity compared to similar criteria (e.g., histopathological examina-
tion and/or microbiological culture from blood or sterile material) [11, 15]. In the present
study, we used the 2008 EORTC/MSG criteria for both IA and IC [20], and 3 (1.3%) of 78
patients had an IC diagnosis based on histology only. Unlike us, Friedrich et al. [18] exclusively
used mycological culture from blood as a reference standard. Although blood culture serves to
document the proven presence of invasive fungal infection [20], three patients with false-posi-
tive BDG results in the study by Friedrich et al. had negative blood cultures but were positive
for the mannan antigen [18], which is a highly specific serum biomarker for IC [26]. Further-
more, fungal antigen levels in the blood are generally higher in culture-positive cases, so the
inclusion of patients based on a blood culture positive may not allow a correct appraisal of the
BDG performance [23]. In our study, the median (IQR) value of galactomannan OD index in
40 patients diagnosed with probable IA was 1.6 (1.3–2.1), giving a measure of moderately high
fungal burdens in these patients. This could indicate later infection stages in these patients—
that in turn could result in higher BDG values—unless the exposure to mold-active antifungal
prophylaxis in many patients could have masked their actual galactomannan levels [8].
Ultimately, for all analyses, we used a mixed control group of patients with different (albeit
partially overlapping) risk factors for IFD [8, 27], which could skew the BDG diagnostic
parameters. To exclude this possibility, we performed a rough analysis using control sub-
groups. Interestingly, we found no one or slight differences in specificities when they were cal-
culated with patients only at risk of IC (97.6% [FA] and 99.4% [GT]), IA (100% for both FA
and GT), or PJP (99.1% [FA] and 100% [GT]) (data not shown).
Unlike IA, where the low sensitivity (60.0%) makes the GT not suitable for diagnosis using
the manufacturer’s recommended cutoff value of 11 pg/mL, the sensitivities of the GT in IC
(91.0%) and PJP (88.2%) were already good without lowering the cutoff value. However, the
GT sensitivity in IA increased to 80.0% with a positivity threshold of 7.0 pg/mL and without
compromising specificity (97.3%). Applying the 7.0-pg/mL cutoff value, the GT sensitivity also
increased for both IC (from 91.0% to 98.7%) and PJP (from 88.2% to 94.1%), whereas at this
cutoff the specificity for both IC and PJP slightly decreased (from 99.5% to 97.3%). Interest-
ingly, the GT cutoff value proposed in this study was almost twice the value proposed else-
where, such as 3.8 in candidemia [18] and 3.616 in PJP [17]. Of note, our value also
encompasses IA, and this is not surprising because BDG testing for yeast or yeast-like fungi
such as Candida species and P. jirovecii may require a cutoff value different from that required
for molds such as Aspergillus species. Accordingly, cutoffs to optimize the performance of the
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BDG assay may be different depending on the pathogen and host [14]. Therefore, it should be
mandatory to interpret BDG results in relation to not only the specific pathogen, but also the
specific patient population [28].
Our comparison of two BDG assays showed that both quantitative correlation and qualita-
tive agreement between the FA and the GT were very good. However, one of the assays failed
to categorize patients correctly. In particular, 13 IA, 7 IC, and 2 PJP samples provided false
negative results only with the GT, because the BDG content in these samples did not reach the
positivity threshold recommended by the manufacturer. Lowering the GT cutoff value allowed
us to recover 5 IA, 6 IC, and 1 PJP samples as true positive samples, thereby indicating that the
manufacturer’s cutoff value might not be appropriate for patients with IA, IC, and PJP. This
was in agreement with the observations reported elsewhere [17, 18].
With the present study, we aimed to provide further data about the role of serum BDG in
the diagnosis of IFDs by means of a comparative assessment of both assays in terms of sensitiv-
ity and specificity using a large number of patient samples. However, we acknowledge the
unavoidable limitations of the study. First, we did not explore whether lower sensitivity of the
GT, particularly in IA samples, could be due to the use of serum instead of plasma, which the
GT manual has listed as a principal specimen for clinical investigation. Nevertheless, we previ-
ously showed that serum samples effectively equate plasma samples for BDG measured with
GT in patients with probable or proven fungal diseases [19]. Second, we did not assess the
predictive value of both assays because of the artificially high prevalence of IFD in our test pop-
ulation influencing the value. However, we well know that, at least for candidemia, high sensi-
tivity and negative predictive value for serum BDG are both helpful to exclude disease in order
to withhold treatment [29]. Third, we waived to compare both assays for important features
such as their layout and workflow. However, we experimented that GT is technically less com-
plex than the FA regarding the possibility either of testing samples individually or up to 16
samples in parallel, as well as the use of a standard curve provided by the manufacturer and,
above all, more simplicity to execute the assay. Fourth, unlike previous studies [17, 18], the
number of PJP case tested by us was very small.
In conclusion, while confirming the good diagnostic accuracy of serum BDG assay [30],
our findings support and/or extend the diagnostic value of both FA and GT into clinical set-
tings such as IA, IC, and PJP. We show that the GT performed almost as the FA after optimiz-
ing the GT cutoff value for positivity. Further studies are yet necessary to establish the
equivalence of both assays in order to provide equally reliable BDG results that can ultimately
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